Helping children with Lowe syndrome see better

CRISPR Based Rescue of Glaucoma in Lowe Syndrome

NIH-funded research Stanford University · NIH-11081645

This research explores a new gene-editing method to help children with Lowe syndrome who are at risk of losing their vision due to glaucoma.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionStanford University NIH-funded
Lab location1 site (Stanford, United States)
Project IDNIH-11081645 on NIH RePORTER

What this research studies

Children with Lowe syndrome often develop cataracts and glaucoma, which can lead to blindness, and currently, there are no specific treatments for this condition. This project is developing a new way to use gene-editing technology to correct the underlying problem in Lowe syndrome. By targeting specific genes, the goal is to restore balance in the cells and prevent vision loss. Researchers are using human stem cells and animal models to test these new approaches.

Who could benefit from this research

Good fit: This research is focused on understanding and treating Lowe syndrome, particularly in children aged 0-11 years old who are affected by the condition.

Not a fit: Patients without Lowe syndrome or those whose vision loss is due to other causes would not directly benefit from this specific research.

Why it matters

Potential benefit: If successful, this work could lead to the first effective treatment to prevent blindness in children with Lowe syndrome.

How similar studies have performed: This project is developing a novel gene-editing approach for Lowe syndrome, as there are currently no therapies for this condition.

Where this research is happening

Stanford, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Breast Cancer Anti-Estrogen Resistance 1 Protein
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.